![](https://monteverdelaw.com/wp-content/uploads/case-logo/ngm-biopharmaceuticals-inc.png)
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM), relating to its proposed sale to affiliates of The Column Group, LP. Under the terms of the agreement, NGM shareholders are expected to receive $1.55 in cash per share they own.
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM), relating to its proposed sale to affiliates of The Column Group, LP. Under the terms of the agreement, NGM shareholders are expected to receive $1.55 in cash per share they own.